Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the... | April 26, 2023
United States Andrew Faughnan Bradley Campbell Johnf Crowley Diana Moore European Commission Approval Of Opfolda
Source: marketscreener.com